Loading…
Karolinska University Hospital
Major Nordic academic site with strong registry & RWE capabilities.
About
Karolinska University Hospital in Stockholm pairs strong clinical research with Sweden's high-quality national registries, enabling robust real-world-evidence and registry-based randomized trials across many therapeutic areas.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Trial readiness iCounts how many of the 9 trial-type capabilities this site lists (Phase 1-4, first-in-human, device, observational, registry and real-world evidence studies) - each adds 5 points, capped at 36 - plus 3 points per study type supported, capped at 34, and 2 points per therapeutic area, capped at 30. Levels: 80+ Comprehensive site | 60-79 Broad capability | 40-59 Established | below 40 Emerging. Whether this dimension matters for you depends on your specific project.
71Broad capability
Recruitment iBlends annual patient volume (1 point per 300 patients, up to 35), recruitment success rate (0.25 points per percent, up to 25), retention rate (0.2 points per percent, up to 20) and referral network size (1 point per 5 referring providers, up to 20). Unreported metrics count as zero. Levels: 80+ High-enrolling | 60-79 Strong | 40-59 Moderate | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Developing
Investigator depth iAdds 1 point per 2 investigators (principal plus sub-investigators combined), capped at 30, plus 1 point per 40 publications, capped at 25, 1 point per 8 completed studies, capped at 25, and 5 points per key opinion leader on staff, capped at 20. Levels: 80+ Renowned | 60-79 Deep | 40-59 Established | below 40 Emerging. Whether this dimension matters for you depends on your specific project.
0Emerging
Operational eff. iStarts from average study startup time - the score is 112 minus 0.45 points per startup day, so faster activation scores higher - with a 6-point bonus for contract turnaround of 30 days or less and another 6 for query resolution within 5 days. Shows Not reported when no startup time is on file. Levels: 80+ Fast startup | 60-79 Efficient | 40-59 Standard | below 40 Slow. Whether this dimension matters for you depends on your specific project.
0Not reported
Digital maturity iCounts how many of the 7 digital trial capabilities this site lists (eSource, ePRO, eConsent, remote monitoring, telemedicine, wearables and decentralized trials) - each adds 15 points, so all 7 reach the 100-point cap. Levels: 80+ Fully digital | 60-79 Advanced | 40-59 Developing | below 40 Traditional. Whether this dimension matters for you depends on your specific project.
90Fully digital
Compliance iAdds 25 points for GCP compliance, 15 each for CAPA management, a QMS and data-integrity controls, plus 7 points per accreditation listed, capped at 20, and an inspection bonus from the last inspection outcome (10 points for no findings, 6 for minor findings only). Levels: 80+ Inspection-ready | 60-79 Strong | 40-59 Established | below 40 Developing. Whether this dimension matters for you depends on your specific project.
84Inspection-ready
Research capabilities
Phase IPhase IIPhase IIIPhase IVDevice trialsObservationalRegistryReal-world evidence
Study types
Phase IIPhase IIIPhase IVObservationalReal-world evidenceMedical deviceOncology
Therapeutic areas
OncologyCardiologyNeurologyEndocrinologyImmunologyRare DiseasesRespiratory
Languages
SwedishEnglish
Live record · illustrative seed data · scores deterministic, rules-based — not AI.